Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2022_LYSA_Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials
DOI: 10.1080/10428194.2022.2032038
En savoir plus
Lysa
2022_LYSA_Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?
DOI: 10.1016/S2666-7568(22)00150-7
En savoir plus
Lysa
2022_LYSA_Peripheral T-Cell Lymphomas: Therapeutic Approaches
DOI: 10.3390/cancers14092332
En savoir plus
Lysa
2022_LYSA_The EHA Research Roadmap: Malignant Lymphoid Diseases
DOI: 10.1097/HS9.0000000000000726
En savoir plus
Lysa
2022_LYSA_Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality
DOI: 10.3390/cancers14102392
En savoir plus
Lysa
2022_LYSA_Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
DOI: 10.1182/blood.2021014506
En savoir plus
Lysa
2022_LYSA_The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target‑Mediated Drug Disposition
DOI: 10.1007/s40262-021-01081-3
En savoir plus
Lysa
2022_LYSA_Chapter 22: Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma
DOI: 10.1007/978-3-030-94353-0_22
En savoir plus
Lysa
2022_LYSA_Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
DOI: 10.1097/HS9.0000000000000675
En savoir plus
Lysa
2022_LYSA_What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
DOI: 10.1097/HS9.0000000000000680
En savoir plus
Lysa
2022_LYSA_PET imaging: back in the game for gastric EMZL?
doi: 10.1182/blood.2021013964.
En savoir plus
Lysa
2022_LYSA_Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
J Clin Oncol 2022 Jan 6;JCO2101777. doi: 10.1200/JCO.21.01777
En savoir plus
Lysa
2022_LYSA_Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy
Blood . 2022 Apr 14;139(15):2338-2346.
En savoir plus
Lysa
2021_LYSA_The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA
Blood Advances 2021
En savoir plus
Lysa
2021_LYSA_Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides linger disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from LyMA prospective trial
Bone Marrow Transplant . 2021 Jul;56(7):1700-1709.
En savoir plus
Lysa
2021_LYSA_Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies
Br J Haematol . 2021 Jul;194(2):382-392.
En savoir plus
Lysa
2021_LYSA_Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche
Blood . 2021 Jul 8;138(1):57-70.
En savoir plus
Lysa
2021_LYSA_Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP
Blood Adv . 2021 Aug 10;5(15):2965-2968.
En savoir plus
Lysa
2021_LYSA_High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B
Am J Surg Pathol . 2021 Oct 1;45(10):1324-1336.
En savoir plus
Lysa
2021_LYSA_Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study
Blood Adv . 2021 Oct 12;5(19):3862-3872.
En savoir plus
Lysa
2021_LYSA_Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)
J Clin Oncol . 2021 Oct 10;39(29):3251-3260.
En savoir plus
Lysa
2021_LYSA_Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumor volume prediction using a convolutional neural network
Eur J Nucl Med Mol Imaging . 2021 May;48(5):1362-1370. doi: 10.1007/s00259-020-05080-7.
En savoir plus
Lysa
2021_LYSA_Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
Blood . 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750.
En savoir plus
Lysa
2021_LYSA_Lenalidomide tiggers T-cell effector functions in vivo in patients with follicular lymphoma
Blood Adv . 2021 Apr 27;5(8):2063-2074.
En savoir plus